Mauritio
Member
- Joined
- Feb 26, 2018
- Messages
- 5,669
This study included several thousand people and followed up with them after 10 years .The chance of developing valvualr heart disease was a tiny bit higher when on bromocriptine (0.34%) compared to the controll group which was 0.29%.
"Within 10 years of follow-up, 11 patients (0.34%, 95% CI 0.13-0.55%) and 44 controls (0.29%, 95% CI 0.20-0.37) met the primary endpoint of heart valve disease..."
- Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine - PubMed
No significant findings even in cabergoline, bromocriptine was even safer than that.
"Mitral tenting area was significantly higher in CBG than in BRC and CTR. None of the valvar abnormalities was associated with symptoms. In conclusion, patients with prolactinomas treated with either CBG or BRC showed higher prevalence of trace and mild Tri or Mi regurgitation, but these findings were not clinically significant.
- A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas - PubMed
Not sure what the dosage was here unfortunetly.
"Bromocriptine seems not to be a safe alternative for patients receiving cabergoline treatment who have preexisting or diagnosed abnormalities suggesting valvular, interstitial myocardial, or pulmonary fibrosis. Further studies are needed to investigate the possible impact of DA treatment on pulmonary arterial pressure."
- Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment - PubMed
There was a signficant association of bromocriptine ,especially in the higher dosages, although it was dose dependant. The mean daily dosage was 18.6mg!
I think that is way higher than what most people outside of parkinsons disease take and likely the reason for their clinical finding. This is corroborated by the fact that the study below alassociation so looked at PD-patients and found no to valvular heart disease. They used lower dosages.
"The development of mild and moderate-severe valvular heart disease in the bromocriptine group also showed a cumulative dose-response relationship. These results suggest that the higher the exposure to bromocriptine, the higher the risk of developing both mild and moderate-severe valvular regurgitations."
In this study they failed to find a correlation . The daily dosage was 8.5mg ,so more than twice as low as in the study above. So somehwheren between 8-18mg seems to be the cut-off dose for valvular heart disease when using bromocriptine. But as the authors said there has to be more research on that to be able to name the dosage more precicsely that causes issues.
"Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed."
- Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists - PubMed
"Within 10 years of follow-up, 11 patients (0.34%, 95% CI 0.13-0.55%) and 44 controls (0.29%, 95% CI 0.20-0.37) met the primary endpoint of heart valve disease..."
- Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine - PubMed
No significant findings even in cabergoline, bromocriptine was even safer than that.
"Mitral tenting area was significantly higher in CBG than in BRC and CTR. None of the valvar abnormalities was associated with symptoms. In conclusion, patients with prolactinomas treated with either CBG or BRC showed higher prevalence of trace and mild Tri or Mi regurgitation, but these findings were not clinically significant.
- A comparison of cabergoline and bromocriptine on the risk of valvular heart disease in patients with prolactinomas - PubMed
Not sure what the dosage was here unfortunetly.
"Bromocriptine seems not to be a safe alternative for patients receiving cabergoline treatment who have preexisting or diagnosed abnormalities suggesting valvular, interstitial myocardial, or pulmonary fibrosis. Further studies are needed to investigate the possible impact of DA treatment on pulmonary arterial pressure."
- Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment - PubMed
There was a signficant association of bromocriptine ,especially in the higher dosages, although it was dose dependant. The mean daily dosage was 18.6mg!
I think that is way higher than what most people outside of parkinsons disease take and likely the reason for their clinical finding. This is corroborated by the fact that the study below alassociation so looked at PD-patients and found no to valvular heart disease. They used lower dosages.
"The development of mild and moderate-severe valvular heart disease in the bromocriptine group also showed a cumulative dose-response relationship. These results suggest that the higher the exposure to bromocriptine, the higher the risk of developing both mild and moderate-severe valvular regurgitations."
In this study they failed to find a correlation . The daily dosage was 8.5mg ,so more than twice as low as in the study above. So somehwheren between 8-18mg seems to be the cut-off dose for valvular heart disease when using bromocriptine. But as the authors said there has to be more research on that to be able to name the dosage more precicsely that causes issues.
"Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed."
- Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists - PubMed